Feds, AbbVie Agree Drug Delay Case Belongs In 3rd Circ.
Both the Federal Trade Commission and AbbVie have urged the Third Circuit not to move an antitrust case focused on delays to generic competition for AndroGel to the Federal Circuit simply because...To view the full article, register now.
Already a subscriber? Click here to view full article